瑞巴派特药理作用及临床应用研究进展
|
摘要
瑞巴派特是一种胃黏膜保护剂,近年来,研究者对其在功能性消化不良、慢性胃炎、NSAID诱导的胃肠损伤、幽门螺杆菌根除治疗后的胃溃疡、内镜手术后的胃溃疡和溃疡性结肠炎中的效应进行了基础、临床研究,对瑞巴派特的多重药理作用进行了分子水平机制的探讨。本文就其药理作用及临床应用研究进展进行总结,以期为临床用药提供参考。
In recent years,several basic and clinical studies are performed about the effect of rebamipide,a protective agent of gastric mucosa,on functional dyspepsia,chronic gastritis,NSAID-induced gastrointestinal injuries,gastric ulcer after eradication therapy for Helicobacter pylori,gastric ulcer after endoscopic surgery and ulcerative colitis. In addition,the multiple pharmacological action of rebamipide is discussed by the mechanism of molecular levels. The article summarizes pharmacological action and clinical application of rebamipide to provide reference for clinical medication.
In recent years,several basic and clinical studies are performed about the effect of rebamipide,a protective agent of gastric mucosa,on functional dyspepsia,chronic gastritis,NSAID-induced gastrointestinal injuries,gastric ulcer after eradication therapy for Helicobacter pylori,gastric ulcer after endoscopic surgery and ulcerative colitis. In addition,the multiple pharmacological action of rebamipide is discussed by the mechanism of molecular levels. The article summarizes pharmacological action and clinical application of rebamipide to provide reference for clinical medication.
引文
[1]刘永军,梅浙川.瑞巴派特的药理作用机制及临床应用[J].中国药业,2005,14(4):24-26.
[2]Arakawa T,Kobayashi K,Yoshikawa T,et al.Rebamipide:overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing[J].Dig Dis Sci,1998,43(Suppl9):S5-S13.
[3]黄明,张全英,王蒙.瑞巴派特分散片的人体药动学及生物等效性[J].中国医药工业杂志,2015,46(1):48-51.
[4]李国锋,晏媛,周萍,等.肠溶性瑞巴派特壳聚糖胶囊的制备及大鼠口服给药吸收评价[J].沈阳药科大学学报,2008,25(10):776-780.
[5]黄月英,卞俊.瑞巴派特在大鼠胃肠道的吸收动力学研究[J].解放军药学学报,2016,32(2):144-147.
[6]杜奕奇,李兆申,湛先保,等.瑞巴派特治疗慢性非萎缩性胃炎的随机、对照、多中心临床研究[J].中华消化内镜杂志,2008,25(7):353-358.
[7]李敏,银腾达,林彬彬.瑞巴派特治疗慢性胃炎:Meta分析[J].胃肠病学和肝病学杂志,2015,24(6):667-673.
[8]Jaafar MH,Safi SZ,Tan MP,et al.Efficacy of rebamipide in organic and functional dyspepsia:a systematic review and M eta-analysis[J].Dig Dis Sci,2018,63(5):1250-1260.
[9]杨瑛英.瑞巴派特辅助治疗老年胃溃疡的可行性及对溃疡复发率的影响[J].现代医药卫生,2017,33(12):1824-1825.
[10]周劲峰,叶婷婷,张昌林.克拉霉素、阿莫西林、兰索拉唑三联疗法联合瑞巴派特治疗老年消化性胃溃疡效果及对胃黏膜形态学的影响[J].中国老年学杂志,2015,35(21):6171-6173.
[11]刘新尧,王晓辉,闫志辉,等.瑞巴派特治疗幽门螺杆菌阳性胃溃疡90例的疗效及细胞因子变化[J].中国新药杂志,2018,27(7):812-816.
[12]Bunno M,Gouda K,Yamahara K,et al.A case-control study of esomeprazole plus rebamipide vs.omeprazole plus rebamipide on post-ESD gastric ulcers[J].Jpn Clin M ed,2013,4:7-13.
[13]Fujiwara S,Morita Y,Toyonaga T,et al.A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection[J].JGastroenterol,2011,46(5):595-602.
[14]Takayama M,Matsui S,Kawasaki M,et al.Efficacy of treatment w ith rebamipide for endoscopic submucosal dissection-induced ulcers[J].World J Gastroenterol,2013,19(34):5706-5712.
[15]张少君,董小林.PPI联合瑞巴派特促进内镜黏膜下剥离术术后溃疡愈合的疗效分析[J].胃肠病学和肝病学杂志,2016,25(6):686-690.
[16]丁叶舟,刘菲,但自力.质子泵抑制剂与瑞巴派特联合治疗ESD术后溃疡疗效随机对照试验的M eta分析[J].世界华人消化杂志,2015,23(16):2629-2636.
[17]朱明辉,缪林.瑞巴派特片联合兰索拉唑片预防胃内镜黏膜下剥离术中及术后出血的效果[J].吉林医学,2016,37(9):2246-2247.
[18]Kim HK,Kim JI,Kim JK,et al.Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers[J].Dig Dis Sci,2007,52(8):1776-1782.
[19]田笑笑,杜浩,郑玉峰,等.埃索美拉唑与瑞巴派特联合使用在预防非甾体抗炎药相关性胃黏膜损伤中的疗效研究[J].中国全科医学,2013,16(20):2407-2409.
[20]王昌雄,王济纬,朱雅碧,等.瑞巴派特和埃索美拉唑防治非甾体抗炎药胃病的疗效对比[J].中国中西医结合消化杂志,2013,21(11):591-592.
[21]刘国华.瑞巴派特与埃索美拉唑联合用于非甾体抗炎药胃炎的临床效果比较[J].航空航天医学杂志,2016,27(2):226-227.
[22]Watanabe T,Takeuchi T,Handa O,et al.A multicenter,randomized,double-blind,placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-tosevere small intestinal damage[J].PLo S One,2015,10(4):e0122330.
[23]Tozawa K,Oshima T,Okugawa T,et al.A randomized,double-blind,placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin w ith or w ithout clopidogrel[J].Dig Dis Sci,2014,59(8):1885-1890.
[24]Nagano Y,Matsui H,Muramatsu M,et al.Rebamipide significantly inhibits indomethacin-induced mitochondrial damage,lipid peroxidation,and apoptosis in gastric epithelial RGM-1cells[J].Dig Dis Sci,2005,50(Suppl 1):S76-S83.
[25]Zhang S,Qing Q,Bai Y,et al.Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy:a systematic review and meta-analysis[J].Dig Dis Sci,2013,58(7):1991-2000.
[26]段兆涛,张振玉,吴海露,等.瑞巴派特对阿司匹林所致人胃黏膜上皮细胞损伤的保护作用及其机制[J].中华消化杂志,2014,34(7):453-457.
[27]王传伟,王凌,陈路佳,等.瑞巴派特对药物所致胃黏膜上皮细胞GES-1损伤的保护作用及其机制[J].世界华人消化杂志,2015,23(16):2588-2593.
[28]刁兴元,李文英,张强泽.瑞巴派特灌肠治疗溃疡性结肠炎的疗效及其机制[J].山东医药,2009,49(29):53-54.
[29]Makiyama K,Takeshima F,Kawasaki H,et al.Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis:a novel therapeutic alternative[J].Am J Gastroenterol,2000,95(7):1838-1839.
[30]Makiyama K,Takeshima F,Hamamoto T.Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis:a prospective study report[J].Dig Dis Sci,2005,50(12):2323-2329.
[31]于海燕,于琳,方宝霞,等.瑞巴派特保留灌肠治疗溃疡性结肠炎疗效的Meta分析[J].山西医药杂志,2013,42(1):87-89.
[32]徐进,杨洁,王斌,等.瑞巴派特对实验性结肠炎大鼠肠道黏膜的保护作用[J].胃肠病学和肝病学杂志,2016,25(7):745-748.
[33]王欣,柯碧莲.黏蛋白分泌激动剂在干眼治疗中的研究进展[J].中国眼耳鼻喉科杂志,2017,17(6):427-430,435.
[34]Kashima T,Itakura H,Akiyama H,et al.Rebamipide ophthalmic suspension for the treatment of dry eye syndrome:a critical appraisal[J].Clin Ophthalmol,2014,8:1003-1010.
[35]Kinoshita S,Oshiden K,Awamura S,et al.A randomized,multicenter phase 3 study comparing 2%rebamipide(OPC-12759)w ith 0.1%sodium hyaluronate in the treatment of dry eye[J].Ophthalmology,2013,120(6):1158-1165.
[36]Igarashi T,Kobayashi M,Yaguchi C,et al.Efficacy of rebamipide instillation for contact lens discomfort w ith dry eye[J].Eye Contact Lens,2018,44(Suppl 2):S137-S142.
[37]Igarashi A,Kamiya K,Kobashi H,et al.Effect of rebamipide ophthalmic suspension on intraocular light scattering for dry eye after corneal refractive surgery[J].Cornea,2015,34(8):895-900.
[38]Matsuda T,Ohno S,Hirohata S,et al.Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients w ith Behc,et's disease:a randomised,double-blind,placebo-controlled study[J].Drugs R D,2003,4(1):19-28.
[39]Kpd M,Nsvr D,Koppal S,et al.Efficacy of rebamipide and levamisole in the treatment of patients w ith recurrent aphthous ulcer-a comparative study[J].J Clin Diagn Res,2014,8(11):ZC119-ZC122.
[40]Fukuhara K,Terakura M,Katsuragi K,et al.The effects of rebamipide and polaprezinc mouthw ash and uptake on mucositis induced by chemotherapy[J].Gan To Kagaku Ryoho,2011,38(13):2603-2606.
[41]Ishii N,Kawano Y,Sakai H,et al.Effects of a rebamipide mouthw ash on stomatitis caused by cancer chemotherapy-evaluation of the efficacy by patients themselves[J].Yakugaku Zasshi,2017,137(8):1027-1034.
[42]Yokota T,Ogawa T,Takahashi S,et al.Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients w ith head and neck cancer:a multicenter,randomized,double-blind,placebo-controlled,parallel-group phase II study[J].BM C Cancer,2017,17(1):314.
[43]松田贵邦,佐古信朋,中岛贵子,等.用于治疗口腔疾病的包含瑞巴派特的药物组合物[P].中国专利:CN103429224A,2013-12-04.
[44]闵俊基,曹美罗,禹润珠,等.用于预防或治疗风湿性关节炎的含有瑞巴派特的药物组合物[P].中国专利:CN102481298A,2012-05-30.
[45]闵俊基,曺美罗,禹润珠,等.含有瑞巴派特作为有效成分的用于预防或治疗骨关节炎的药学组合物[P].中国专利:CN102791272A,2012-11-21.
[46]王传栋,王勤,杨清华,等.一种治疗阴道干涩症的药物及其制备方法[P].中国专利:CN102240260A,2011-11-16.
[47]Min DS.A potential efficacy of rebamipide as anti-gastric cancer drug[J].J Life Sci,2016,26(10):1214-1217.
[2]Arakawa T,Kobayashi K,Yoshikawa T,et al.Rebamipide:overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing[J].Dig Dis Sci,1998,43(Suppl9):S5-S13.
[3]黄明,张全英,王蒙.瑞巴派特分散片的人体药动学及生物等效性[J].中国医药工业杂志,2015,46(1):48-51.
[4]李国锋,晏媛,周萍,等.肠溶性瑞巴派特壳聚糖胶囊的制备及大鼠口服给药吸收评价[J].沈阳药科大学学报,2008,25(10):776-780.
[5]黄月英,卞俊.瑞巴派特在大鼠胃肠道的吸收动力学研究[J].解放军药学学报,2016,32(2):144-147.
[6]杜奕奇,李兆申,湛先保,等.瑞巴派特治疗慢性非萎缩性胃炎的随机、对照、多中心临床研究[J].中华消化内镜杂志,2008,25(7):353-358.
[7]李敏,银腾达,林彬彬.瑞巴派特治疗慢性胃炎:Meta分析[J].胃肠病学和肝病学杂志,2015,24(6):667-673.
[8]Jaafar MH,Safi SZ,Tan MP,et al.Efficacy of rebamipide in organic and functional dyspepsia:a systematic review and M eta-analysis[J].Dig Dis Sci,2018,63(5):1250-1260.
[9]杨瑛英.瑞巴派特辅助治疗老年胃溃疡的可行性及对溃疡复发率的影响[J].现代医药卫生,2017,33(12):1824-1825.
[10]周劲峰,叶婷婷,张昌林.克拉霉素、阿莫西林、兰索拉唑三联疗法联合瑞巴派特治疗老年消化性胃溃疡效果及对胃黏膜形态学的影响[J].中国老年学杂志,2015,35(21):6171-6173.
[11]刘新尧,王晓辉,闫志辉,等.瑞巴派特治疗幽门螺杆菌阳性胃溃疡90例的疗效及细胞因子变化[J].中国新药杂志,2018,27(7):812-816.
[12]Bunno M,Gouda K,Yamahara K,et al.A case-control study of esomeprazole plus rebamipide vs.omeprazole plus rebamipide on post-ESD gastric ulcers[J].Jpn Clin M ed,2013,4:7-13.
[13]Fujiwara S,Morita Y,Toyonaga T,et al.A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection[J].JGastroenterol,2011,46(5):595-602.
[14]Takayama M,Matsui S,Kawasaki M,et al.Efficacy of treatment w ith rebamipide for endoscopic submucosal dissection-induced ulcers[J].World J Gastroenterol,2013,19(34):5706-5712.
[15]张少君,董小林.PPI联合瑞巴派特促进内镜黏膜下剥离术术后溃疡愈合的疗效分析[J].胃肠病学和肝病学杂志,2016,25(6):686-690.
[16]丁叶舟,刘菲,但自力.质子泵抑制剂与瑞巴派特联合治疗ESD术后溃疡疗效随机对照试验的M eta分析[J].世界华人消化杂志,2015,23(16):2629-2636.
[17]朱明辉,缪林.瑞巴派特片联合兰索拉唑片预防胃内镜黏膜下剥离术中及术后出血的效果[J].吉林医学,2016,37(9):2246-2247.
[18]Kim HK,Kim JI,Kim JK,et al.Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers[J].Dig Dis Sci,2007,52(8):1776-1782.
[19]田笑笑,杜浩,郑玉峰,等.埃索美拉唑与瑞巴派特联合使用在预防非甾体抗炎药相关性胃黏膜损伤中的疗效研究[J].中国全科医学,2013,16(20):2407-2409.
[20]王昌雄,王济纬,朱雅碧,等.瑞巴派特和埃索美拉唑防治非甾体抗炎药胃病的疗效对比[J].中国中西医结合消化杂志,2013,21(11):591-592.
[21]刘国华.瑞巴派特与埃索美拉唑联合用于非甾体抗炎药胃炎的临床效果比较[J].航空航天医学杂志,2016,27(2):226-227.
[22]Watanabe T,Takeuchi T,Handa O,et al.A multicenter,randomized,double-blind,placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-tosevere small intestinal damage[J].PLo S One,2015,10(4):e0122330.
[23]Tozawa K,Oshima T,Okugawa T,et al.A randomized,double-blind,placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin w ith or w ithout clopidogrel[J].Dig Dis Sci,2014,59(8):1885-1890.
[24]Nagano Y,Matsui H,Muramatsu M,et al.Rebamipide significantly inhibits indomethacin-induced mitochondrial damage,lipid peroxidation,and apoptosis in gastric epithelial RGM-1cells[J].Dig Dis Sci,2005,50(Suppl 1):S76-S83.
[25]Zhang S,Qing Q,Bai Y,et al.Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy:a systematic review and meta-analysis[J].Dig Dis Sci,2013,58(7):1991-2000.
[26]段兆涛,张振玉,吴海露,等.瑞巴派特对阿司匹林所致人胃黏膜上皮细胞损伤的保护作用及其机制[J].中华消化杂志,2014,34(7):453-457.
[27]王传伟,王凌,陈路佳,等.瑞巴派特对药物所致胃黏膜上皮细胞GES-1损伤的保护作用及其机制[J].世界华人消化杂志,2015,23(16):2588-2593.
[28]刁兴元,李文英,张强泽.瑞巴派特灌肠治疗溃疡性结肠炎的疗效及其机制[J].山东医药,2009,49(29):53-54.
[29]Makiyama K,Takeshima F,Kawasaki H,et al.Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis:a novel therapeutic alternative[J].Am J Gastroenterol,2000,95(7):1838-1839.
[30]Makiyama K,Takeshima F,Hamamoto T.Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis:a prospective study report[J].Dig Dis Sci,2005,50(12):2323-2329.
[31]于海燕,于琳,方宝霞,等.瑞巴派特保留灌肠治疗溃疡性结肠炎疗效的Meta分析[J].山西医药杂志,2013,42(1):87-89.
[32]徐进,杨洁,王斌,等.瑞巴派特对实验性结肠炎大鼠肠道黏膜的保护作用[J].胃肠病学和肝病学杂志,2016,25(7):745-748.
[33]王欣,柯碧莲.黏蛋白分泌激动剂在干眼治疗中的研究进展[J].中国眼耳鼻喉科杂志,2017,17(6):427-430,435.
[34]Kashima T,Itakura H,Akiyama H,et al.Rebamipide ophthalmic suspension for the treatment of dry eye syndrome:a critical appraisal[J].Clin Ophthalmol,2014,8:1003-1010.
[35]Kinoshita S,Oshiden K,Awamura S,et al.A randomized,multicenter phase 3 study comparing 2%rebamipide(OPC-12759)w ith 0.1%sodium hyaluronate in the treatment of dry eye[J].Ophthalmology,2013,120(6):1158-1165.
[36]Igarashi T,Kobayashi M,Yaguchi C,et al.Efficacy of rebamipide instillation for contact lens discomfort w ith dry eye[J].Eye Contact Lens,2018,44(Suppl 2):S137-S142.
[37]Igarashi A,Kamiya K,Kobashi H,et al.Effect of rebamipide ophthalmic suspension on intraocular light scattering for dry eye after corneal refractive surgery[J].Cornea,2015,34(8):895-900.
[38]Matsuda T,Ohno S,Hirohata S,et al.Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients w ith Behc,et's disease:a randomised,double-blind,placebo-controlled study[J].Drugs R D,2003,4(1):19-28.
[39]Kpd M,Nsvr D,Koppal S,et al.Efficacy of rebamipide and levamisole in the treatment of patients w ith recurrent aphthous ulcer-a comparative study[J].J Clin Diagn Res,2014,8(11):ZC119-ZC122.
[40]Fukuhara K,Terakura M,Katsuragi K,et al.The effects of rebamipide and polaprezinc mouthw ash and uptake on mucositis induced by chemotherapy[J].Gan To Kagaku Ryoho,2011,38(13):2603-2606.
[41]Ishii N,Kawano Y,Sakai H,et al.Effects of a rebamipide mouthw ash on stomatitis caused by cancer chemotherapy-evaluation of the efficacy by patients themselves[J].Yakugaku Zasshi,2017,137(8):1027-1034.
[42]Yokota T,Ogawa T,Takahashi S,et al.Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients w ith head and neck cancer:a multicenter,randomized,double-blind,placebo-controlled,parallel-group phase II study[J].BM C Cancer,2017,17(1):314.
[43]松田贵邦,佐古信朋,中岛贵子,等.用于治疗口腔疾病的包含瑞巴派特的药物组合物[P].中国专利:CN103429224A,2013-12-04.
[44]闵俊基,曹美罗,禹润珠,等.用于预防或治疗风湿性关节炎的含有瑞巴派特的药物组合物[P].中国专利:CN102481298A,2012-05-30.
[45]闵俊基,曺美罗,禹润珠,等.含有瑞巴派特作为有效成分的用于预防或治疗骨关节炎的药学组合物[P].中国专利:CN102791272A,2012-11-21.
[46]王传栋,王勤,杨清华,等.一种治疗阴道干涩症的药物及其制备方法[P].中国专利:CN102240260A,2011-11-16.
[47]Min DS.A potential efficacy of rebamipide as anti-gastric cancer drug[J].J Life Sci,2016,26(10):1214-1217.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |